DENTSPLY SIRONA INC (XRAY)
US24906P1093 - Common Stock
Taking everything into account, XRAY scores 4 out of 10 in our fundamental rating. XRAY was compared to 187 industry peers in the Health Care Equipment & Supplies industry. While XRAY is still in line with the averages on profitability rating, there are concerns on its financial health. XRAY is cheap, but on the other hand it scores bad on growth. Finally XRAY also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
In the past year XRAY was profitable.
XRAY had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: XRAY reported negative net income in multiple years.
XRAY had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
XRAY's Return On Assets of -6.23% is fine compared to the rest of the industry. XRAY outperforms 63.10% of its industry peers.
XRAY has a better Return On Equity (-16.58%) than 62.57% of its industry peers.
The Return On Invested Capital of XRAY (4.09%) is better than 75.40% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for XRAY is below the industry average of 8.19%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.23% | ||
| ROE | -16.58% | ||
| ROIC | 4.09% |
ROA(3y)-3.26%
ROA(5y)-1.52%
ROE(3y)-6.9%
ROE(5y)-3.43%
ROIC(3y)4.86%
ROIC(5y)4.47%
1.3 Margins
XRAY has a better Operating Margin (6.74%) than 73.26% of its industry peers.
In the last couple of years the Operating Margin of XRAY has declined.
XRAY has a Gross Margin (52.18%) which is comparable to the rest of the industry.
XRAY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.74% | ||
| PM (TTM) | N/A | ||
| GM | 52.18% |
OM growth 3Y-3.46%
OM growth 5Y-3.12%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.16%
GM growth 5Y0.32%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), XRAY is destroying value.
The number of shares outstanding for XRAY has been reduced compared to 1 year ago.
Compared to 5 years ago, XRAY has less shares outstanding
The debt/assets ratio for XRAY is higher compared to a year ago.
2.2 Solvency
XRAY has an Altman-Z score of 1.26. This is a bad value and indicates that XRAY is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.26, XRAY is in line with its industry, outperforming 48.13% of the companies in the same industry.
The Debt to FCF ratio of XRAY is 6.07, which is on the high side as it means it would take XRAY, 6.07 years of fcf income to pay off all of its debts.
XRAY's Debt to FCF ratio of 6.07 is fine compared to the rest of the industry. XRAY outperforms 76.47% of its industry peers.
XRAY has a Debt/Equity ratio of 0.72. This is a neutral value indicating XRAY is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.72, XRAY is doing worse than 71.12% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.72 | ||
| Debt/FCF | 6.07 | ||
| Altman-Z | 1.26 |
ROIC/WACC0.49
WACC8.26%
2.3 Liquidity
XRAY has a Current Ratio of 1.25. This is a normal value and indicates that XRAY is financially healthy and should not expect problems in meeting its short term obligations.
XRAY has a worse Current ratio (1.25) than 85.03% of its industry peers.
A Quick Ratio of 0.84 indicates that XRAY may have some problems paying its short term obligations.
The Quick ratio of XRAY (0.84) is worse than 86.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.25 | ||
| Quick Ratio | 0.84 |
3. Growth
3.1 Past
XRAY shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
Measured over the past years, XRAY shows a decrease in Earnings Per Share. The EPS has been decreasing by -1.86% on average per year.
Looking at the last year, XRAY shows a decrease in Revenue. The Revenue has decreased by -0.91% in the last year.
Measured over the past years, XRAY shows a decrease in Revenue. The Revenue has been decreasing by -0.11% on average per year.
EPS 1Y (TTM)0%
EPS 3Y0.74%
EPS 5Y-1.86%
EPS Q2Q%2.04%
Revenue 1Y (TTM)-0.91%
Revenue growth 3Y5.9%
Revenue growth 5Y-0.11%
Sales Q2Q%0.42%
3.2 Future
XRAY is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.82% yearly.
Based on estimates for the next years, XRAY will show a small growth in Revenue. The Revenue will grow by 1.81% on average per year.
EPS Next Y2.38%
EPS Next 2Y3.68%
EPS Next 3Y7.24%
EPS Next 5Y12.82%
Revenue Next Year-2.87%
Revenue Next 2Y-2.2%
Revenue Next 3Y-0.45%
Revenue Next 5Y1.81%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
XRAY is valuated reasonably with a Price/Earnings ratio of 10.22.
Compared to the rest of the industry, the Price/Earnings ratio of XRAY indicates a rather cheap valuation: XRAY is cheaper than 96.79% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 27.37. XRAY is valued rather cheaply when compared to this.
The Price/Forward Earnings ratio is 9.61, which indicates a very decent valuation of XRAY.
97.33% of the companies in the same industry are more expensive than XRAY, based on the Price/Forward Earnings ratio.
XRAY's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.85.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.22 | ||
| Fwd PE | 9.61 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, XRAY is valued cheaply inside the industry as 96.26% of the companies are valued more expensively.
96.26% of the companies in the same industry are more expensive than XRAY, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.3 | ||
| EV/EBITDA | 9.34 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates XRAY does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)4.29
PEG (5Y)N/A
EPS Next 2Y3.68%
EPS Next 3Y7.24%
5. Dividend
5.1 Amount
XRAY has a Yearly Dividend Yield of 3.47%. Purely for dividend investing, there may be better candidates out there.
The stock price of XRAY dropped by -29.94% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
Compared to an average industry Dividend Yield of 1.68, XRAY pays a better dividend. On top of this XRAY pays more dividend than 98.93% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.36, XRAY pays a bit more dividend than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.47% |
5.2 History
The dividend of XRAY is nicely growing with an annual growth rate of 9.48%!
XRAY has been paying a dividend for at least 10 years, so it has a reliable track record.
XRAY has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)9.48%
Div Incr Years5
Div Non Decr Years29
5.3 Sustainability
The earnings of XRAY are negative and hence is the payout ratio. XRAY will probably not be able to sustain this dividend level.
XRAY's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP-30.27%
EPS Next 2Y3.68%
EPS Next 3Y7.24%
DENTSPLY SIRONA INC
NASDAQ:XRAY (12/24/2024, 1:00:56 PM)
After market: 18.9 -0.01 (-0.05%)18.91
-0.04 (-0.21%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners108.57%
Inst Owner Change-1.77%
Ins Owners0.25%
Ins Owner Change-0.11%
Market Cap3.76B
Analysts76.19
Price Target24.91 (31.73%)
Short Float %4.31%
Short Ratio2.51
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.47% |
Dividend Growth(5Y)9.48%
DP-30.27%
Div Incr Years5
Div Non Decr Years29
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.64%
Min EPS beat(2)-3.31%
Max EPS beat(2)4.59%
EPS beat(4)1
Avg EPS beat(4)-0.19%
Min EPS beat(4)-3.31%
Max EPS beat(4)4.59%
EPS beat(8)4
Avg EPS beat(8)8.47%
EPS beat(12)5
Avg EPS beat(12)3.71%
EPS beat(16)9
Avg EPS beat(16)7.06%
Revenue beat(2)0
Avg Revenue beat(2)-1.89%
Min Revenue beat(2)-3.05%
Max Revenue beat(2)-0.72%
Revenue beat(4)1
Avg Revenue beat(4)-1.45%
Min Revenue beat(4)-3.59%
Max Revenue beat(4)1.57%
Revenue beat(8)4
Avg Revenue beat(8)-0.64%
Revenue beat(12)4
Avg Revenue beat(12)-2.22%
Revenue beat(16)7
Avg Revenue beat(16)-0.76%
PT rev (1m)-22.37%
PT rev (3m)-23.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-25.21%
EPS NY rev (1m)-4.37%
EPS NY rev (3m)-7.21%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-10.28%
Revenue NY rev (1m)-0.54%
Revenue NY rev (3m)-1.79%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.22 | ||
| Fwd PE | 9.61 | ||
| P/S | 0.96 | ||
| P/FCF | 10.3 | ||
| P/OCF | 7.04 | ||
| P/B | 1.51 | ||
| P/tB | N/A | ||
| EV/EBITDA | 9.34 |
EPS(TTM)1.85
EY9.78%
EPS(NY)1.97
Fwd EY10.4%
FCF(TTM)1.84
FCFY9.71%
OCF(TTM)2.69
OCFY14.21%
SpS19.62
BVpS12.53
TBVpS-4.95
PEG (NY)4.29
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.23% | ||
| ROE | -16.58% | ||
| ROCE | 5.17% | ||
| ROIC | 4.09% | ||
| ROICexc | 4.34% | ||
| ROICexgc | 15.82% | ||
| OM | 6.74% | ||
| PM (TTM) | N/A | ||
| GM | 52.18% | ||
| FCFM | 9.36% |
ROA(3y)-3.26%
ROA(5y)-1.52%
ROE(3y)-6.9%
ROE(5y)-3.43%
ROIC(3y)4.86%
ROIC(5y)4.47%
ROICexc(3y)5.12%
ROICexc(5y)4.71%
ROICexgc(3y)23.93%
ROICexgc(5y)23.2%
ROCE(3y)6.16%
ROCE(5y)5.66%
ROICexcg growth 3Y-8.57%
ROICexcg growth 5Y-2.64%
ROICexc growth 3Y12.82%
ROICexc growth 5Y2.18%
OM growth 3Y-3.46%
OM growth 5Y-3.12%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.16%
GM growth 5Y0.32%
F-Score4
Asset Turnover0.59
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.72 | ||
| Debt/FCF | 6.07 | ||
| Debt/EBITDA | 2.95 | ||
| Cap/Depr | 48.84% | ||
| Cap/Sales | 4.33% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 87.68% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.25 | ||
| Quick Ratio | 0.84 | ||
| Altman-Z | 1.26 |
F-Score4
WACC8.26%
ROIC/WACC0.49
Cap/Depr(3y)43.3%
Cap/Depr(5y)38.81%
Cap/Sales(3y)3.64%
Cap/Sales(5y)3.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y0.74%
EPS 5Y-1.86%
EPS Q2Q%2.04%
EPS Next Y2.38%
EPS Next 2Y3.68%
EPS Next 3Y7.24%
EPS Next 5Y12.82%
Revenue 1Y (TTM)-0.91%
Revenue growth 3Y5.9%
Revenue growth 5Y-0.11%
Sales Q2Q%0.42%
Revenue Next Year-2.87%
Revenue Next 2Y-2.2%
Revenue Next 3Y-0.45%
Revenue Next 5Y1.81%
EBIT growth 1Y-10.85%
EBIT growth 3Y2.24%
EBIT growth 5Y-3.22%
EBIT Next Year21.54%
EBIT Next 3Y10.46%
EBIT Next 5Y10.15%
FCF growth 1Y-16.86%
FCF growth 3Y-25.97%
FCF growth 5Y-6.07%
OCF growth 1Y-10.55%
OCF growth 3Y-16.56%
OCF growth 5Y-5.48%